TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells is a research paper published in European Urology Oncology (2022). On theSindex it has a DataRank of 3.3. It has been cited 88 times, with 83 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.673
From this paper's citation signal
Citation Network Contribution
2.6
From 70 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 83 citers.
NCI NIH HHS
Grant: R01 CA235741
NIGMS NIH HHS
Grant: T32 GM141323
National Institutes of Health
Grant: 1R01CA235741-01A1
MELT: Modulation of PSMA Expression for Lutetium Therapy
National Institutes of Health
Grant: 5T32GM141323-03
Medical Scientist Training Program (T32 NRSA Training Grant)
FWCI
16.04
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals